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Vascular smwtb muscle cell hyperplasis i  a major component 01 
atherogrwsis in various animal models. Aogiopptin, a cyclic 
cuapeptidc analague ol wmatostatin, markedly inhibits myointi. 
mat pwtiferetian In response to endothdial colt injury in the rat 
carotid srtery, rabbit aorta and iliac srkrios and in coronary 
arteries of transplanted rabbit hearts. Angiopeptin does not atTeet 
serum lipid pm& in nonhuman primates. It is unliiely, there. 
fore, tkat its antiproliferative effect is mediated by cIterations in 
cholesterol metabolism. 
Angiopptin and other pptide annlogues ol somatmtatin are 
potent inhibitors af growth hormone rctensc and inrulin.llke 
grwth factor-I production. However, inhibition of smacth mu* 
de cell proliferation in viva is not a property common to all 
somatostatln s nlogues. This sqgerk that plasma growth bar- 
rthme and grmvib barmanc~dcpcndent insulin4iic growth factor~l 
productton are not physlolc& stimuli for myointtmat pmlifera. 
tion in vlvo. 
Angkpptio inhibits ‘H.thymidino incorporation into rat ~1. 
mtid artery explmk, suggesting a lwal of&t on rubwine or 
parwine mefhanlsms regukting cell growth. In view of its potent 
inhibitory et&cl on smooth mu& ccl replirntkn, attgiopeptin 
may have clinicat utility in preventtng r&en& after prsotane- 
ous trnnslumittsl mmnary sngi~t~ty and in prwentirng accekr- 
akd mronnry atJtcrosekrosis after cardkc tnnsplsntatbm. 
(J Am C’oll Cardial 1991;17:132B-68) 
Peptide Analogues of Somatostatin 
and Atherogenesis 
Experimentally induced myointimal plaque formation rc. 
sembling human atherosclerotic disease has been described 
in various animal models (1.2). After endothelial injury. a 
well described sequence of events occurs, which ultimately 
leads to the formation of a proliferative intimal lesion and 
intraluminal narrowing of the arterial segment. Proliferation 
and subsequent migration of medial smooth muscle cells 
through the arterial internal elastic lamina into the intima are 
major factors resulting in atherosclerotic plaque develop 
ment 0). Although the sequence of events leading to the final 
development of a proliferative arterial lesion has been tem- 
porally and qualitatively described, the mechanisms respon. 
sible for this phenomenon remain poorly understood. 
Whether thia response is under systemic endocrine. para- 
crine or autocrine control remains unknown. 
Platelet-derived growth factor is a peptide growth factor 
found in platelets, and similar compounds are expressed by 
multiple tissues (4-6). Platelet-derived growth factor is a 
potent milogen for smooth muscle cells and is produced by 
smooth muscle cells derived from human atheroma (7.8). 
The platelet.derivcd growth factor rceeptor has tyminc 
kinase activity. and binding of the rcecptor by pla.tek~- 
derived growth factor stimulates multiple intracellular rc- 
sponses, including receptor autophosphorylation, induction 
of “competence” genes necessary for deoxyrit!atuclcic acid 
(DNA) replication and cell replication (9-11). 
Insulin-like growth factor-l, also known as somatomedin 
C. is an endogenous pcptide that stimulates proliferation of 
many cell types, including smooth muscle cells (11.12). 
Exposure of smooth r:wscle cells in culture to platelet- 
derived growth factor results in the release of an insulin.like 
growth factor-l-like pcptide into the medium. which acts in 
B synergistic manner with platelet-derived growth factor to 
stimulate replication (7.1 I). Stiles et al. (12) demonstrated 
that after exposure to platelet-derived growh factor, 
growth-arrested cells become “competent” to replicate lhcir 
DNA. but do not “progress” lo DNA rcplieation unless 
insulin.like growth factor-l is present. Clemmons (7) also 
showed that the presence of insulin-like growth factor.1 is 
the rate-limiting step in smooth muscle cell replication after 
exposure to platelet-derived growth factor. These data sug- 
gest that platelet-derived growth factor and insulin-like 
growth factor-l act in an autocrine or paracrinc manner to 
regulate smooth muscle cell proliferation. 
Tiell et al. (13) demonstrated that hypophysectomy inhib- 
its arterial neointimal plaque formation in response to endo- 
thelial cell injury. This suggests that endocrine factors may 
be necessary for plaque formation. The plasma and local 
tissue concentrations of insulin-like growth factor-l arc 
directly regulated by hypophyseal growth hormone (14.15). 
Administration of growth hormone results in a rapid increase 
in local tissue concentrations of insulin-like growth factor-t 
(1.5). lnhihition of pituitary growth hormone release and the 
consequent reduction in insulin-like growth factor-l tissue 
content are prominent effects of native somatostatin admin- 
istration (16). Native somatostatin also possesses patent 
antiproliferative activity (17). The development of stable. 
relatively long-acting analagues of somatostatin has intro- 
duced a new tool for investigating possible mechanisms that 
regulate cell replication. which may depad on somatomcd- 
ins. 
Several peptide onologues of nnrirc sonmrosmrin have 
been synthesized: these have a high affinity for somatostatin 
recepton in pituitary cells, inhibit pituitary growth hormone 
release, reduce circulating sotttatomedin levels and have 
potent antitumor activity (16.18-20). After subcutaneous 
injection in humans. these compounds are readily absorbed 
into the systemic circulalion. They exhibit a prolonged 
olasma clearance time cornoared with native samatostatin 
i21). One of these anaIog;es has demonstrated marked 
antioroliferative activitv in vitro and in vim. inhibiting small 
cell’lune carcinoma ceil growth (22l. 
As a result of the inhibitory effect of somatostatin on 
insulin-like growth factor-l pmduction and its known an- 
tiproliferative activity. the effect of several peptide ana- 
logues of somatostatin on myointimal proliferation wan 
recently investigated in several animal models. The studies 
have attempted to identify those factors that may be impor- 
tant in regulating smooth muscle cell replication in response 
to arterial injury. 
E&XI of Angiopeptin in a Rat Model of 
Myointimal Proliferation 
Table I shows the amino acid sequence of several hep- 
tapeptide and octapeptide analogues of somatostatin and the 
effect of there agents on myointimal proliferation in the tat 
camtid artery subjected toendothelial injury by an air-drying 
technique (I). The intimalimedia ratio was determined by 
morphometry I5 daysafterinjury. Angiopeptinadministered 
by subcutaneous injection significantly inhibited neointimal 
formation. whether it was administered for 2 days or imme- 
diately (30 min) before injury. BIM-23034. also an octapep 
tide analogue of somatostatin. significantly inhibited neoirr 
rimal formation to a similar extent. The serum half-life of 
each of these peptides is short (approximately Cd3 min). This 
suggesu that continuous expuswe to high levels of circtdat- 
ing peptide analagues of somatostatin is not required to 
significantly inhibit myointimal pmliietation. 
BIM-23030. BIM-23027 and BIM-23012 do not inhibit 
neointimal formation in this model when administered in 
the same doses as awiooeotin and 8111113034. Fach of 
these five peptides is a-pie& inhibitor of pituitary growth 
hormone release. BLU-23027 and BIM-23012 are. respec- 
lively. IO0 and I2 times more potent than angiopeptin with 
respect to growth hormwe suppression (Table I). The 
failure of BIM-23030. BIM-23027 and BIM-23012 to inhibit 
myointimal pmlifet-ation. therefore. suggests that neither 
pituitary-derived growth hormone wx circulating insulin-like 
growth factor-l is a physiologic stimulus fo: smooth muscle 
ce:i proliferation in viva in response to endothelial cell 
injury. 
Mechanism. Angiopeptin and BIM-23034 may have a 
direct effect on proliferating smooth muscle cells in viva 16). 
Vargar et al. (24) demonstrated that angiopptin in micro- 
molar quantities rignificamly inhibits ‘H-thymidine incorpo- 
ration into explants of rat carotid arteries after endothelial 
denudation. These data suggest hat the inhibitory effect of 
aqiopeptin on myointimal proliferation is mediated by 
means of an effect on autocrine or paracrine processes that 
regulate cell replication. This possibility remains to be 
investigated. 
Table 1. Efect of Angiopeplin 69 &day) and Placebo n Lipid Deposition of Donor Ascending Aorta. Native Ascending Aana, Native 
Thoracic Aorta and Native Abdominal Aorta in the Rabbit 
Effect of Angiopeptin in Rabbit Models of 
Myointimal Proliferation 
Accelerated coronary atherosclerosis in cardiac allogr&ts 
occurs in a significant proportion of cardiac transplants 
(25.26). The pathogenesis of atherosclerosis in this set&g is 
unknown. but it may be related to endothelial cell iniurv 
secondary to harvest&, reperfusion or rejection. The e&i1 
of angiopeptin on “accelerated atherogenesis” has been 
examined in a rabbit cardiac transplant model of alhcroscle- 
rosis (271. 
Angiopeptin. in a dose approximating 20 &kg per day, 
significantly inhibited coronary artery myointimal prolifera- 
tion in cardiac allografts in New Zealand White rabbits by 
appmximalely 50% (27). Angiopeptin also significantly in- 
hibited the develooment of coronarv intimal hvoernlasia in 
the native heart ofihe allograft recipient, although tda lesser 
degree (27). 
Table 2 shows the effect ofangiopeptin on lipid deposition 
in the donor and native ascending aonas as well as the native 
thoracic and abdominal aorta in the rabbit cardiac transplant 
model of atherosclerosis. Angiopeptin significantly inhibits 
lipid deposition in the donor and native ascending aortas. Of 
nore is the >50% inhibition of lipid deposition in the donor 
ascending aorta, which is extensively involved with athero- 
sclerosis. 
In contrast, Table 3 shows the effect of angiopeptin an 
serum lip;? profiles in cynomolgus macaca fed a I% choles 
terol-supplemented iet. Angiopeptin failed to alter serum 
lipids in this species. Angiopeptin may therefore inhibit lipid 
deposition in injured arterial segments independent of an 
e&cl on cholesterol metabolism. 
Meehsnism. The mechanism by which angiopeptin inhib- 
its coronary anery intimal hyperplasia and lipid deposition in 
rabbit cardiac allografts is unknown. Native somatostatin 
has immunomcdulatory activity, including inhibition of lym- 
phocyte proliferation (18). Binding sites for native somato- 
s’alin are present an monocytes (29). In addition, native 
somatostatin and a ptent analogue of somatostatin have 
been shown to enhance the fornmtion of leukocyte migra- 
lion-inhibiting factor (30). However. the effect of angiopep 
tin on lymphocyte and nwnwyte activity has not been 
investigated. An immunosuppressive ffect cannot be as- 
sumed because angiopeptin does not prolong cardiac al- 
lograft survival (31). However, this hypothesis has not been 
directly tested. 
Table 4 illustrates the effect of angiopeptin (20 &kg per 
day) on myointimal proliferation in rabbit aorta and iliac 
arteries deendatheliilized with a balloon catheter. Angio- 
neDtin sieniftcantlv inhibits neointima formation in male and 
&ale rabbit &Is. Asotra et al. (33) demonstrated that 
the effect of aneiocatin on neointimal formation is due to 
inhibition of Vance& smooth muscle cell proliferation by 
showing that angiapeptin markedly inhibits )H-thymidine 
incorporation into balloon-denuded labbit aorta. 
Conclusions 
Angiopeptin. a cyclic octapeptide analogue of native 
somatostatin, is a potent inhibitor of myointimal prolifer,- 
lion in response to endothelial cell injury in several animal 
models. The failure of similar peptide analogues of somato- 
stain to inhibit neointimal formation suggests that the mech- 
anism of action of augiopeptin is not due to inhibition of 
pituitary growth hormone release or a reduction in hypophy- 
seal growth hormone-dependent insulin-like growth factor-l 
production. or both. Inhibition of smooth muscle replication 
in vitro by angiopeptin suggests that angiopeptin may inhibit 
an autwine or paracrine mechanism that regulates cell 
replication. Heiman et al. (18) identified two subtypes of 
somatostatin receptors present in the cerebral cortex and 
pituitary gland, respectively. The specificity foi ligand bind- 
ing was distinctly different for each of these receptor sub 
types. The tiiand-binding requirements for somatostatin 
receptors on smooth muscle cells are unknown at present. 
However, the presence of a receptor with a high at%nity for 
binding attgiopeptin preferentially over other sotttatostatin 
attalogttes could explain the unique inhibitory activity of this 
substance. 
Mammatory cells such as ntonocytes aqd lymphocytes 
are among the cellular wmpvnents involved in the arterial 
response to injury (34). lnflummutory cells prcduce multiple 
types ofgmwth factors. including interleukins. transforming 
gmwtb factors, interferons and platelet-derived growth fac- 
ior (34.35). Native somatostat~tt has immunomodulatory 
activitv. includine inhibition of lvmphocvte pmliferation and 
stimul;liion of leukocyte migtat~on~nhibiti~g factor (28.30). 
Whether angiopeptin possesses immunomodutatory activity 
is not known. However, if angiopeptin does atTect intlam- 
matory cell function, this may provide a possible explanation 
for its effect MI smooth muscle cell proliferation in viva. This 
hypothesis remains to be tested. 
Hiemwski et al. (36) rewrted that in a pancreatic cancer 
cell line, somatostatin activates dzphos~horylation of a 
phosphotyrosyl membrane protein that exhibits tyrosine 
kinaoe activily and is pho,phorylated in response to epider- 
mal growth factor binding. Many local growth factors. 
ineluding platelet-derived growth factor and insulin-like 
growth factor-l, stimulate tyrorine kinase activity common 
to their respective receptors. apparently in association with 
cell pr&iieration (37). It remains to be tested whether the 
inhibitory effect of angiopeptin on smooth muscle cell pro- 
liferation is associated with inhibition of growth factor 
receptor autophosphorylation. 
Clinical ulitity. Angiopeptin may have immediate clinical 
utility. Percutaneous coronary and peripheral arterial angio- 
plasty and atherectomy are utilized extensively in the lreat- 
ment of obstructive atherosckmtic disease. Restenosis is a 
significant problem with each of these technologies (38.39). 
Smooth muscle cell pmtiferation is a major comptmmt 
responsible for the resienosis phenometw (4@. On the basis 
of data derived from animat nwkls. angiopeptin could 
potentially reduce the extremely high iocidence of restenosis 
(35.40) observed after amio~last~ and atherectomr (38.39). 
In addition, angiapeptin may be of value in preventing 
accelerated comnaty atherosclerosis aftercardii ttanspian- 
tation. 
Although animal models of myointimal proliferation, such 
as balloon-induced endotheliat injury of normat arterial 
segments. are “artitkiat” by definition and do not exactly 
reproduce the clinical situation present at the time of angio- 
plasty or atherectomy. they do provide valuable insights into 
potential mechanisms of cell gmwlh regulation. We have 
demonstrated that angiqeptin is a potent inhibitor of myw 
intimal proliferation in response to two extremely di&xent 
types of injury in viva (namely. balloon-induced eodothetial 
cell denudation in the rat and rabbit models and immune 
injury in the rabbit transplant model of atherosclerosis). 
Whether this success in the animal laboratory will translate 
into clinical success, preventing restenosis atIer ansioplarty 
or atherectomy. needs to be determined in a controlled 
clinical trial. A multicenter double-blind controlled clinical 
trial that will examine the e&t of angiopeptin on restenosis 
after coronary angioplasty has recently begun in the United 
States. It is hoped that the results of this trial will provide 
further insight into the phenomenon of myointimal proliier- 
ation. 
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